BridgeBio Pharma Inc. (BBIO) Stock Price, News, Analysis | DailyIQ

|

Technical Score (1D)

18

BEARISH

News Sentiment

62

BULLISH

On Oct 7, Barclays analyst Eliana Merle retained an Overweight rating for BridgeBio Pharma while lowering the price target from $157 to $156, reflecting a modest reassessment of the company’s near‑term valuation. On Oct 6, BridgeBio presented new acoramidis data at the Heart Failure Society of America Annual Scientific Meeting, including independent real‑world electronic health record comparisons, in a series of oral presentations, rapid‑fire talks, and poster sessions focused on transthyretin amyloid cardiomyopathy. On the same day, the company announced that additional evidence from the Phase 3 CALIBRATE trial of encaleret in autosomal dominant hypocalcemia type 1 would be presented at the American Society for Bone and Mineral Research Annual Meeting, highlighting further data that could support the therapeutic profile of encaleret. Also on Oct 6, BridgeBio and community partners launched a nationwide education initiative for ATTR‑CM, featuring a YouTube premiere with medical and cultural voices to raise awareness of the condition as an underrecognized cause of heart failure. These developments illustrate BridgeBio’s ongoing efforts to expand its clinical evidence base and maintain investor interest.

BBIO|Analyst Targets

LOW TARGET

$80 +21.2%

2 analysts

MEAN TARGET

$109 +65.3%

10 analysts

HIGH TARGET

$156 +136.4%

19 analysts

PRICE RANGE

$80.00 - $156.00

SB / B / H / S / SS

6/20/3/1/1

DAILYIQ EST.

$117.62 (+78.2%)

BBIO|Insider Trading

Bought (1Y)

0 shares

$0

Sold (1Y)

499,529 shares

$38.7M

Kumar NeilChief Executive Officer

Sell1,279 shares2026-09-17

Kumar NeilChief Executive Officer

Sell8,721 shares2026-09-17

Kumar NeilChief Executive Officer

Sell100 shares2026-08-19

Kumar NeilChief Executive Officer

Sell1,800 shares2026-08-19

Kumar NeilChief Executive Officer

Sell8,100 shares2026-08-19

BBIO|Fundamentals

Bearish

Overall: Bearish

✓Revenue growing year over year

✕Negative net margin

✕Negative operating cash flow

Net Margin

-146.0%

Revenue CAGR

52.1%

Current Ratio

2.77x

Debt / Equity

-0.96x

Return on Equity

35.1%

BBIO|Earnings Snapshot

EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q3'26	$-0.63	-	-
Q2'25	$-0.60	$-0.95	-57.1%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q3'26	$276M	-	-
Q2'25	-	-	-

Full Earnings BreakdownEstimates, actuals, guidance, and historical context

BBIO|Monthly Returns

Market Data

BBIO Stock Snapshot

BEARISH18/100

$65.99−$0.48 (0.7%)

Market cap: 13.06B
Day range: $65.99 – $67.80
News sentiment: 62/100 · Bullish
Analyst target: $109.05 (+65.3%)
Consensus: Buy · 31 analysts

52-week range+25.1% off low · -30.2% from high

$52.75$94.51

Price $65.99 DailyIQ Est. $117.62

BridgeBio Pharma Inc. is trading in the lower half of its 52-week range with momentum still pointing lower. The stock is liquid enough that positioning changes get absorbed without distorting the trend.

Behaviour On Record

What BBIO's own history says about today's numbers

Realized volatility (21d): 43.7% 24th pct
Below its peak: -26.7%
vs 200-day average: -10.2%
Up days (1y): 50%

BridgeBio Pharma Inc. is currently running 43.7% annualised volatility over the last 21 sessions. Measured against BBIO's own 7 years of daily returns rather than a market-wide average, that is the 24th percentile — unusually subdued by its own history, against a typical reading of 57.6%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

BBIO is trading -26.7% below its running peak. Across 6 full years on file, its median worst-drawdown-in-a-year was -50.4%, and the deepest was -80.1% in 2021. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits -10.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 25th percentile — a narrower gap than it typically runs. Over the past year BBIO closed higher on 50% of sessions, and it is currently 1 session into a falling streak.

On October specifically: over 7 years of records, BBIO finished the month higher 5 of 7 times, with a median return of +2.5% and an average of +3.7%. Its strongest month historically has been June at +12.7% on average, its weakest September at -5.5%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: BBIO has opened more than 2% away from the prior close in 332 of 1,823 sessions (18.2% of the time), with the largest gaps running +20.9% and -12.2%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 1,825 daily closes between 2019-06-27 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against BBIO's own 7-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of BBIO's sector?

BridgeBio Pharma Inc. sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (lagging). Within its narrower Biotechnology industry group, BBIO ranks 10th of 15 tracked industries, lagging.

Sector rank: #3 of 12
Sector state: Lagging
Sector rotation score: 64
Industry rank: #10 of 15

Options Market

What is the options market pricing for BBIO?

CallsPuts

For BridgeBio Pharma Inc.'s nearest expiry (2026-10-16, 9 days out), open interest is put-heavy, a defensive/bearish tilt (put/call ratio of 3.91), with at-the-money implied volatility around 60.5%. The options market is pricing roughly a ±11.2% move by that expiry — a range of about $61.28–$76.72.

Put/call ratio (2026-10-16): 3.91
ATM implied volatility: 60.5%
Total open interest: 13,441
Expected move by 2026-10-16: ±11.2% ($61.28–$76.72)

Analyst Rating Changes

Are analysts turning bullish or bearish on BBIO?

Barclays most recently reiterated its rating on BridgeBio Pharma Inc. to Overweight on Oct 7, 2026 with a price target of $156 (from $157). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action: Barclays — Overweight
90-day upgrades: 0
90-day downgrades: 0
Net rating momentum: 0

Date	Firm	Action	Rating	Price target
Oct 7, 2026	Barclays	Maintained	Overweight	$157 → $156
Sep 10, 2026	HC Wainwright & Co.	Reiterated	Buy	$120
Sep 2, 2026	HC Wainwright & Co.	Reiterated	Buy	$120
Sep 1, 2026	Mizuho	Maintained	Outperform	$96 → $110
Aug 12, 2026	Truist Securities	Maintained	Buy	$102 → $107
Aug 12, 2026	Canaccord Genuity	Maintained	Buy	$104 → $106
Aug 12, 2026	JP Morgan	Maintained	Overweight	$100 → $111
Aug 11, 2026	B of A Securities	Maintained	Buy	$101 → $104
Aug 11, 2026	TD Cowen	Maintained	Buy	$95 → $110
Aug 11, 2026	Morgan Stanley	Maintained	Overweight	$98 → $97
Aug 11, 2026	Piper Sandler	Maintained	Overweight	$111 → $115
Aug 11, 2026	Wells Fargo	Maintained	Overweight	$98 → $102

Held by These ETFs

BBIO is a top holding in these ETFs tracked on DailyIQ — bar length shows portfolio weight.

News Sentiment Analysis

Sentiment gathered from recent headlines

62/100

Strong NegativeNeutralStrong Positive

MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

BridgeBio Pharma (BBIO) received FDA priority review for its oral drug infigratinib, targeting achondroplasia. The agency will aim to decide within six months, potentially accelerating market entry. Infigratinib offers a novel mechanism by directly inhibiting FGFR3, contrasting with existing injectable treatments. Phase III PROPEL 3 data showed a 2.1 cm/year height growth advantage over placebo. Approval would position BBIO as a pioneer in oral dwarfism therapy.

What did this article say?

Barclays analyst Eliana Merle retained an Overweight rating for BridgeBio Pharma (BBIO) while reducing the price target from $157 to $156. The downgrade reflects a modest reassessment of the company’s near‑term valuation. The change signals a slight negative outlook but does not alter the overall positive stance on the stock.

What did this article say?

BridgeBio Pharma announced it would present additional data from its Phase 3 CALIBRATE trial of encaleret for autosomal dominant hypocalcemia type 1 at the ASBMR 2026 Annual Meeting. The company plans to discuss patient‑reported outcomes and bone turnover markers, providing a more comprehensive view of the drug’s efficacy. It also intends to showcase findings from regional cascade genetic testing events aimed at delivering no‑cost testing to at‑risk relatives. The presentation is positioned as a step toward further clinical validation rather than a definitive breakthrough.

What did this article say?

BridgeBio Pharma presented new acoramidis data, including independent real‑world EHR comparisons, at the Heart Failure Society of America Annual Scientific Meeting. The company delivered one oral presentation, three rapid‑fire talks, and six poster sessions focused on transthyretin amyloid cardiomyopathy (ATTR‑CM). The data aim to strengthen the clinical evidence base for acoramidis in ATTR‑CM patients.

What did this article say?

BridgeBio Pharma announced a nationwide education initiative to raise awareness of transthyretin amyloid cardiomyopathy (ATTR-CM) on October 6, 2026. The program, launched via a YouTube premiere with community partners, aims to educate the public and healthcare providers about the underrecognized heart failure condition. By highlighting early symptoms and diagnostic challenges, BridgeBio seeks to improve timely recognition and treatment of ATTR-CM. The effort aligns with the company’s focus on genetic diseases and positions BridgeBio as a leader in patient education. No immediate financial or regulatory impact was indicated.

What did this article say?

BridgeBio Pharma (BBIO) announced that the FDA had accepted its New Drug Application for an oral form of Infigratinib to treat achondroplasia, a common genetic cause of short stature. The acceptance included a priority review designation with an expected action date of February 4, 2025. Phase 3 data demonstrated significant improvements in body proportionality and arm span versus placebo, meeting primary and key secondary endpoints. BBIO plans to file for European approval in late 2026. The news contributed to a modest 2.1% rise in premarket trading.

What did this article say?

BridgeBio Pharma received FDA acceptance and priority review for its oral infigratinib NDA targeting children with achondroplasia. The priority review, with a target action date of February 4, 2027, reflects the unmet need for an oral therapy in this population. The decision follows PROPEL 3 trial results showing significant efficacy.

What did this article say?

BridgeBio Pharma, Inc. (BBIO) announced that the U.S. Food and Drug Administration accepted its New Drug Application for oral infigratinib, granting priority review status for the treatment of achondroplasia. The decision allows the company to accelerate the regulatory review process, potentially shortening the time to market. The filing reflects BBIO’s continued focus on developing therapies for genetic disorders and expands its pipeline of oral small‑molecule drugs.

What did this article say?

BridgeBio Pharma announced that the 12‑month interim analysis of its phase 3 Fortify study of oral BBP‑418 had patients with limb‑girdle muscular dystrophy type 2I/R9 reach normal or near‑normal cardiac biomarkers. All treated participants returned to normal HS troponin‑I levels by month 12, compared with 40% in the placebo group, and 54% of treated patients had stable or improved left ventricular ejection fraction versus 25% on placebo. The data support the drug’s safety and efficacy profile and reinforce its priority review status with the FDA, which has a target action date of November 27. The findings suggest a meaningful therapeutic benefit that could accelerate regulatory approval and market entry.

What did this article say?

In exploratory Month‑12 analyses, 100% of LGMD2I patients treated with BBP-418 returned to normal high‑sensitivity troponin I levels, compared with 40% on placebo. The drug also improved left ventricular ejection fraction in 54% of treated patients versus 25% on placebo. These findings suggest BBP-418 may modify disease progression and improve cardiac outcomes in FKRP‑related muscular dystrophy.

Technical Analysis

Real-time indicators across multiple timeframes

18

BEARISH

Technical indicators reflect the latest computed signal mix for this timeframe.

Unlock full technicals

Create a free account to access more indicators and deeper timeframe data.

Institutional & Hedge Fund Ownership

1 tracked managers · $371.07M combined position · 0 adding, 0 trimming, 1 unchanged (latest 13F filings)

Manager	Trend	Shares Held	% of Co.	Position Value	Filed
Citadel Advisors LLC	• Hold	33,326,928	16.84%	$371.07M	2026-09-02

Q2 2026 flow:33.33M sh bought ($371.07M)0 sh sold ($0)net +33.33M sh (+$371.07M)

Congressional Trading Activity

5 disclosed trades · ~$40.0K est. traded value · 5 buys, 0 sells

Member	Chamber	State	Type	Amount	Traded	Filed
Gilbert Cisneros	House	CA31	▲ Buy	$1K - $15K	2026-04-29	2026-05-08
Gilbert Cisneros	House	CA31	▲ Buy	$1K - $15K	2026-03-19	2026-04-07
Gilbert Cisneros	House	CA31	▲ Buy	$1K - $15K	2026-03-18	2026-04-07
Gilbert Cisneros	House	CA31	▲ Buy	$1K - $15K	2026-03-03	2026-04-07
Gilbert Cisneros	House	CA31	▲ Buy	$1K - $15K	2025-09-22	2025-10-10